<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445845</url>
  </required_header>
  <id_info>
    <org_study_id>1608185</org_study_id>
    <secondary_id>2017-004700-22</secondary_id>
    <nct_id>NCT03445845</nct_id>
  </id_info>
  <brief_title>Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis</brief_title>
  <acronym>ROC-SPA</acronym>
  <official_title>Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by&#xD;
      inflammatory arthritis and enthesitis involving the spine. AxSpA prevalence is around 0.17%&#xD;
      of the French population. Tumor necrosis factor (TNF) was the first target defined in axSpA.&#xD;
      Since one third of axSpA patients failed to the first TNF blocker, many axSpA patients&#xD;
      received a second biological Disease-Modifying AntiRheumatic Drugs (bDMARDs). Until few&#xD;
      months, the only choice was to use a second TNF blocker.Since 2003, pharmaceutical companies&#xD;
      investigated efficacy of TNF blockers already used in rheumatoid arthritis. Etanercept is a&#xD;
      fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab,&#xD;
      infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion between a fab&#xD;
      fragment targeting TNF and a Peg fraction. All demonstrated efficacy versus placebo in a&#xD;
      randomized double blinded study&#xD;
&#xD;
      In case of failure to the first TNF blockers, rheumatologists will follow the&#xD;
      &quot;Treat-to-Target&quot; principle. This approach already demonstrated its benefit in rheumatoid&#xD;
      arthritis or in psoriatic arthritis. This concept was also suggested for axSpA with low&#xD;
      levels of evidence and recommendation. So rheumatologist will provide the best treatment in&#xD;
      case of failure to the first TNF blockers, which is a daily clinical situation. Since few&#xD;
      months, rheumatologists have the choice between targeting IL-23/17 axis compared to a second&#xD;
      TNF blocker.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of axSpA patients with a clinical response Assessments in Ankylosing Spondylitis International Society 40 (ASAS 40) at week 24</measure>
    <time_frame>24 weks</time_frame>
    <description>ASAS 40 is defined as an improvement of at least 40% and absolute improvement of at least 2 units on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening at all in remaining domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a clinical response ASAS 40 at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASAS 40 is defined as an improvement of at least 40% and absolute improvement of at least 2 units on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening at all in remaining domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a clinical response ASAS 40 at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>ASAS 40 is defined as an improvement of at least 40% and absolute improvement of at least 2 units on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening at all in remaining domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a clinical response ASAS 20 at week 12</measure>
    <time_frame>52 weeks</time_frame>
    <description>ASAS 20 is defined as an improvement of at least 20% and absolute improvement of at least 1 unit on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions regarding measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening in a similar amount in the fourth domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a clinical response ASAS 20 at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>ASAS 20 is defined as an improvement of at least 20% and absolute improvement of at least 1 unit on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions regarding measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening in a similar amount in the fourth domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a clinical response ASAS20 at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>ASAS 20 is defined as an improvement of at least 20% and absolute improvement of at least 1 unit on a numerical rating scale of 10 in at least 3 of the following domains compared to values at inclusion:&#xD;
Patient global assessment : numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment : average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function : BASFI average of 10 questions regarding measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot; Additionally, no worsening in a similar amount in the fourth domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a partial remission rate at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Partial remission is defined by values lower than 2/10 in each 4 domains:&#xD;
Patient global assessment measured on a numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment represented by the average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function represented by BASFI average of 10 questions regarding ability to perform specific tasks as measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI regarding morning stiffness as measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a partial remission rate at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Partial remission is defined by values lower than 2/10 in each 4 domains:&#xD;
Patient global assessment measured on a numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment represented by the average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function represented by BASFI average of 10 questions regarding ability to perform specific tasks as measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI regarding morning stiffness as measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a partial remission rate at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Partial remission is defined by values lower than 2/10 in each 4 domains:&#xD;
Patient global assessment measured on a numerical rating scale with extremes labelled &quot;none&quot; and &quot;severe.&quot;&#xD;
Pain assessment represented by the average of total and nocturnal pain scores, both measured on a numerical rating scale with extremes labelled &quot;no pain&quot; and &quot;most severe pain.&quot;&#xD;
Function represented by BASFI average of 10 questions regarding ability to perform specific tasks as measured by numerical rating scale with extremes labelled &quot;easy&quot; and &quot;impossible.&quot;&#xD;
Morning stiffness, represented by the average of the last 2 questions on the 6-question BASDAI regarding morning stiffness as measured by numerical rating scale: one with extremes labelled &quot;none&quot; and &quot;very severe&quot;; the other marking duration of morning stiffness between &quot;0&quot; and &quot;2 or more hours.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a ASDAS major improvement at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>ASDAS major improvement was defined by a variation of ASDAS-CRP≥2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a ASDAS major improvement at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>ASDAS major improvement was defined by a variation of ASDAS-CRP≥2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with a ASDAS major improvement at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>ASDAS major improvement was defined by a variation of ASDAS-CRP≥2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with biological Disease-Modifying AntiRheumatic Drugs (bDMARDs) treatment at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient with the same bDAMRs treatment at inclusion and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with biological Disease-Modifying AntiRheumatic Drugs (bDMARDs) treatment at week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patient with the same biological Disease-Modifying AntiRheumatic Drug (bDAMR) treatment at inclusion and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of axSpA patients with bDMARDs treatment at week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>Patient with the same biological Disease-Modifying AntiRheumatic Drug (bDAMR) treatment at inclusion and week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between concentration of antibodies to bDMARS blockers and clinical response according to treatment</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>Concentration of antibodies to bDMARS blockers is measured by Enzyme Linked ImmunoSorbent Assay (ELISA) low disease activity is defined by BASDAI &lt;4 and ASDAS &lt;2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between concentration of anti-drug antibodies and clinical response according to treatment</measure>
    <time_frame>From baseline to 52 weeks</time_frame>
    <description>Concentration of anti-drug antibodies is measured by Enzyme Linked ImmunoSorbent Assay (ELISA) low disease activity is defined by BASDAI &lt;4 and ASDAS &lt;2.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>targeting IL-23/17 axis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.&#xD;
Blood specimen at each visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNF blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:&#xD;
The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:&#xD;
infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,&#xD;
etanercept: 50mg per week in subcutaneous injection,&#xD;
adalimumab: 40mg every other week in subcutaneous injection,&#xD;
certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,&#xD;
golimumab: 50mg every month in subcutaneous injection, in case of overweight (&gt;100kg) an inadequate response, 100mg every month is allow.&#xD;
Blood specimen at each visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection</description>
    <arm_group_label>targeting IL-23/17 axis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF blocker</intervention_name>
    <description>TNF blocker (originator or biosimilar) :&#xD;
infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,&#xD;
etanercept: 50mg per week in subcutaneous injection,&#xD;
adalimumab: 40mg every other week in subcutaneous injection,&#xD;
certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,&#xD;
golimumab: 50mg every month in subcutaneous injection, in case of overweight (&gt;100kg) an inadequate response, 100mg every month is allow.</description>
    <arm_group_label>TNF blocker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood specimen</intervention_name>
    <description>Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration</description>
    <arm_group_label>TNF blocker</arm_group_label>
    <arm_group_label>targeting IL-23/17 axis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active axSPA with BASDAI&gt;4 or ASDAS&gt;3.5, who need change in TNF blocker treatment&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  Inadequate response after at least 3 months to the 1st TNF blocker&#xD;
&#xD;
          -  If non biologic DMARD treatment : stable dose for at least on month before inclusion&#xD;
&#xD;
          -  If oral corticosteroids treatment : stable dose for at least on month before inclusion&#xD;
&#xD;
          -  If NSAIDs treatment : stable dose for at least on month before inclusion&#xD;
&#xD;
          -  Ability to complete questionnaires&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Informed written consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contra-indication to TNF blocker and/or secukinumab&#xD;
&#xD;
          -  Inflammatory bowel diseases&#xD;
&#xD;
          -  Existing pregnancy, lactation, or intended pregnancy within the next 15 months Active&#xD;
             tuberculosis or other severe infections such as sepsis or opportunistic infections&#xD;
&#xD;
          -  Active infections, including chronic or localised infections.&#xD;
&#xD;
          -  Moderate to severe heart failure (NYHA classes III/IV)&#xD;
&#xD;
          -  Impossibility to give informed consent&#xD;
&#xD;
          -  Impossibility to be followed for 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert MAROTTE, MD</last_name>
    <phone>04 77 12 76 49</phone>
    <phone_ext>+33</phone_ext>
    <email>hubert.marotte@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON</last_name>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Wendling, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Wendling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP- Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luca Semerano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Schaeverbeke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Schaeverbeke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Devauchelle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valérie Devauchelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dewi GUELLEC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain SARAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Tournadre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Tournadre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Athan Gaudin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Grégoire CORMIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent ANDRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel CAULIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline COZIC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emeline GAIGNEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexia MICHAUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane VARIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Dernis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle Dernis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie Denis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Diriez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René-Marc Flipo, MD</last_name>
    </contact>
    <investigator>
      <last_name>René-Marc Flipo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Philibert</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tristan PASCART, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Lyon SUD</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabienne COURY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roland CHAPURLAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Lukas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cédric Lukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - 2 - Unité Clinique thérapeutique des Maladies Ostéo-Articulaires</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christian JORGENSEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanna FERREIRA LOPEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves-Marie PERS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien Loeuille, MD</last_name>
    </contact>
    <investigator>
      <last_name>Damien Loeuille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît Le Goff, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoît Le Goff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Garraud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Maugars, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Roux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Roux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Lespessailles, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Lespessailles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexei Volguine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Ambroise Paré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Breban, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maxime Breban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariane Leboime Grigaut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Dieudé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Dieudé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Miceli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corinne Miceli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Claudepierre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Claudepierre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Richette, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Richette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure Gossec</last_name>
    </contact>
    <investigator>
      <last_name>Laure Gossec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie Sellam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérémie Sellam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Deprouw, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Kremlin-Bicêtre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Pavy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Pavy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabika Belkhir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Desmoulins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Henry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaetane Nocturne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaèle Seror, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth Solau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth Solau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Lequerré, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Lequerré, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Marotte, MD</last_name>
      <phone>+33 4 77 12 76 49</phone>
      <email>hubert.marotte@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert Marotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Constantin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud Constantin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Goupille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saloua Mammou-Mraghni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica René, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Princesse de Grace</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Brocq, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Brocq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNF blocker</keyword>
  <keyword>change of biotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

